Barroso-Sousa, Romualdo
Tarantino, Paolo http://orcid.org/0000-0001-8686-0228
Tayob, Nabihah
Dang, Chau http://orcid.org/0000-0001-5133-2265
Yardley, Denise A.
Isakoff, Steven J.
Valero, Vicente
Faggen, Meredith
Mulvey, Therese
Bose, Ron
Hu, Jiani
Weckstein, Douglas
Wolff, Antonio C. http://orcid.org/0000-0003-3734-1063
Reeder-Hayes, Katherine
Rugo, Hope S.
Ramaswamy, Bhuvaneswari http://orcid.org/0000-0002-2822-8379
Zuckerman, Dan
Hart, Lowell
Gadi, Vijayakrishna K.
Constantine, Michael
Cheng, Kit
Briccetti, Frederick
Schneider, Bryan
Garrett, Audrey Merrill
Marcom, Kelly http://orcid.org/0000-0001-5302-6368
Albain, Kathy
DeFusco, Patricia
Tung, Nadine
Ardman, Blair
Nanda, Rita http://orcid.org/0000-0001-5248-0876
Jankowitz, Rachel C. http://orcid.org/0000-0001-7691-2389
Rimawi, Mothaffar http://orcid.org/0000-0002-4284-5656
Abramson, Vandana
Pohlmann, Paula R. http://orcid.org/0000-0001-7914-5162
Van Poznak, Catherine http://orcid.org/0000-0001-5523-6908
Forero-Torres, Andres
Liu, Minetta http://orcid.org/0000-0002-8206-5232
Ruddy, Kathryn J. http://orcid.org/0000-0001-6298-332X
Zheng, Yue http://orcid.org/0000-0002-2294-813X
Rosenberg, Shoshana M.
Gelber, Richard D.
Trippa, Lorenzo
Barry, William
DeMeo, Michelle
Burstein, Harold
Partridge, Ann http://orcid.org/0000-0002-4722-4824
Winer, Eric P. http://orcid.org/0000-0002-8819-1723
Krop, Ian http://orcid.org/0000-0002-6380-5944
Tolaney, Sara M. http://orcid.org/0000-0002-5940-8671
Funding for this research was provided by:
Genentech
Susan G. Komen
Article History
Received: 29 September 2021
Accepted: 14 January 2022
First Online: 16 February 2022
Competing interests
: Romualdo Barroso-Sousa: Consulting fees (e.g., advisory boards): AstraZeneca, Eli Lilly, Libbs, Merck, Roche, Zodiac. Fees for non-CME services received directly from commercial interest or their Agents (e.g., speakers’ bureaus): Bard Access, BMS, Eli Lilly, Libbs, Merck, Novartis, Pfizer, Roche. Research funding (to institution)<i>:</i> Roche, BMS. Travel/accommodation/expenses<i>:</i> Eli Lilly, Roche, Daichi Sankyo, Merck. Paolo Tarantino: Consulting or advisory role<i>:</i> AstraZeneca. Chau Dang. Honoraria: Puma Biotechnology, eviCore healthcare. Consulting or advisory role: Puma Biotechnology, eviCore healthcare. Research funding: Genentech/Roche, Puma Biotechnology. Denise Yardley. Consulting or advisory role: Novartis, Biotheranostics, Bristol Myers Squibb, G1 Therapeutics, Athenex, Immunomedics, Sanofi/Aventis, R-Pharm, Lilly. Speakers’ Bureau: Novartis, Genentech/Roche, Genentech/Roche. Research funding<i>:</i> Genentech/Roche, Novartis, MedImmune, Lilly, Medivation, Pfizer, Tesaro, Macrogenics, AbbVie, Merck, Clovis Oncology, Amgen, Biomarin, Biothera, Dana-Farber Cancer Hospital, Incyte, Innocrin Pharma, Nektar, NSABP Foundation, Odonate Therapeutics, Polyphor. Travel, accommodations, expenses: Novartis, Genentech/Roche. Steven Isakoff. Consulting or advisory role: AbbVie, OncoPep, Puma Biotechnology, Seattle Genetics, Novartis. Research funding: Genentech, PharmaMar, AbbVie, OncoPep, Merck, AstraZeneca/MedImmune, Outcomes4Me. Vicente Valero. Honoraria: Genentech/Roche, Merck, Novartis. Consulting or advisory role: Genentech/Roche, Novartis, Merck<i>.</i> Travel, accommodations, expenses: Genentech/Roche. Therese Mulvey. Consulting or advisory role: Outcomes4Me. Ron Bose. Consulting or advisory role: Genentech. Research funding<i>:</i> Puma Biotechnology. Antonio Wolff. Consulting or advisory role: Ionis Pharmaceuticals. Research funding: Biomarin, Celldex. Patents, Royalties, Other Intellectual Property: Antonio Wolff has been named as an inventor on one or more issued patents or pending patent applications related to methylation in breast cancer and has assigned his rights to JHU and participates in a royalty sharing agreement with JHU. Open payments link: ExternalRef removed. Katherine Reeder-Hayes. Research funding: Pfizer. Hope Rugo. Honoraria: Puma Biotechnology, Mylan. Consulting or advisory role: Samsung. Research funding: Macrogenics, OBI Pharma, Eisai, Pfizer, Novartis, Lilly, Genentech, Merck, Immunomedics, Odonate Therapeutics, Daiichi Sankyo, Seattle Genetics, Sermonix Pharmaceuticals, AstraZeneca. Travel, accommodations, expenses: Pfizer, Novartis, Macrogenics, Mylan, Daiichi Sankyo, AstraZeneca Spain, Merck. Open payments link: ExternalRef removed. Bhuvaneswari Ramaswamy. Consulting or advisory role: Eisai. Lowell Hart. Honoraria: Novartis, Daiichi Sankyo, AstraZeneca, Seattle Genetics, G1 Therapeutics, Veracyte, Karyopharm Therapeutics. Consulting or advisory role: Genentech/Roche, Amgen, G1 Therapeutics, Merck, Seattle Genetics. Speakers’ Bureau: Bristol Myers Squibb, Lilly, Pfizer, Genentech, AstraZeneca, Novartis. Research funding<i>:</i> Novartis, Genentech/Roche, Bristol Myers Squibb, G1 Therapeutics, Seattle Genetics. Vijayakrishna Gadi. Stock and other ownership interests: Sengine precision medicine, Novilla, 3rdEyeBio, New Equilibrium Biosciences, Phoenix Molecular Designs. Consulting or advisory role: Seattle Genetics, Puma Biotechnology, Sanofi, Hologics. Speakers’ Bureau: Seagen, Puma, Genentech/Roche. Research funding: Agendia (to institution). Travel, accommodations, expenses: Puma, Seagen, Genentech/Roche. Open payments link: ExternalRef removed. Bryan Schneider. Honoraria: Lilly, Research to Practice. Paul Marcom. Consulting or advisory role: Genentech/Roche, Immunomedics. Research funding: Novartis, Genentech/Roche, AstraZeneca, Verily, Glycomimetics, Millennium. Open payments link: ExternalRef removed. Kathy Albain. Consulting or advisory role<i>:</i> Novartis, Pfizer, Myriad Genetics, Genomic Health, Agendia, Genentech/Roche. Research funding: Seattle Genetics. Other relationship: Puma Biotechnology. Nadine Tung. Research funding: AstraZeneca. Rita Nanda. Consulting or advisory role: Merck, Genentech/Roche, Pfizer, Macrogenics, Daiichi Sankyo, Athenex, Aduro Biotech, ION Pharma, Seattle Genetics, Immunomedics. Research funding: Corcept Therapeutics, Celgene, Merck, Seattle Genetics, Genentech/Roche, Odonate Therapeutics, Pfizer, AstraZeneca, AbbVie, Immunomedics. Other relationship: G1 Therapeutics. Rachel Jankowitz. Honoraria: Eisai. Consulting or advisory role<i>:</i> Merck. Mothaffar Rimawi. Consulting or advisory role: Macrogenics, Daiichi Sankyo, Seattle Genetics, Genentech. Research funding: Pfizer. Vandana Abramson. Employment: HCA Healthcare. Consulting or advisory role: Eisai, Daiichi Sankyo, Abbvie. Research funding: Genentech/Roche, Lilly. Paula Pohlmann. Leadership<i>:</i> Immunonet BioSciences. Stock and other ownership interests<i>:</i> Immunonet BioSciences. Honoraria: Dava Oncology, OncLive/MJH Life Sciences, Frontiers—Publisher. Consulting or advisory role: Personalized Cancer Therapy, OncoPlex Diagnostics, Immunonet BioSciences, Pfizer, HERON, Puma Biotechnology, Sirtex Medical, Caris Life Sciences, Juniper Pharmaceuticals, Bolt Biotherapeutics. Speakers’ Bureau: Genentech/Roche. Research Funding: Genentech/Roche, Fabre-Kramer, Advanced Cancer Therapeutics, Caris Centers of Excellence, Pfizer, Pieris Pharmaceuticals, Cascadian Therapeutics, Bolt Biotherapeutics, Byondis, Seagen. Patents, Royalties, Other Intellectual Property<i>:</i> United States Patent no. 8486413, United States Patent no. 8501417, United States Patent no. 9023362, United States Patent no. 9745377, Patent application. Catherine Van Poznak. Research funding: Bayer. Patents, Royalties, Other Intellectual Property: UpToDate. Andres Forero-Torres. Employment<i>:</i> Seattle Genetics. Stock and other ownership interests: Seattle Genetics. Minetta Liu. Research funding: Eisai, Seattle Genetics, Novartis, Roche/Genentech, GRAIL, Merck, Tesaro, Menarini Silicon Biosystems, Genomic Health. Travel, accommodations, expenses: GRAIL, Merck, Menarini Silicon Biosystems, Pfizer, Genomic Health, AstraZeneca, Ionis Pharmaceuticals. Kathryn Ruddy. Patents, Royalties, Other Intellectual Property: My husband is a co-inventor of technology licensed by Mayo Clinic to AliveCor (MountainView, CA), which makes a smartphone-enabled remote ECG monitoring system. Richard Gelber. Research funding: AstraZeneca, Novartis, Roche, Merck, Pfizer. Travel, accommodations, expenses: Roche, AstraZeneca, Novartis. Bill Barry. Employment<i>:</i> Rho. Ann Partridge. Patents, Royalties, Other Intellectual Property: I receive small royalty payments for co-authoring the breast cancer survivorship section of UpToDate. Travel, accommodations, expenses: Novartis. Eric Winer. Honoraria: Genentech/Roche, Genomic Health. Consulting or advisory role: Leap Therapeutics, Seattle Genetics, Jounce Therapeutics, GlaxoSmithKline, Carrick Therapeutics, Lilly, G1 Therapeutics, Syros Pharmaceuticals, Genentech/Roche, Gilead Sciences, Zymeworks, Athenex. Research funding: Genentech. <i>Other</i> Relationship: InfiniteMD. Ian Krop. Employment: AMAG Pharmaceuticals, Freeline Therapeutics. Leadership: AMAG Pharmaceuticals, Freeline Therapeutics. Stock and other ownership interests: AMAG Pharmaceuticals, Freeline Therapeutics, Vertex. Honoraria: Genentech/Roche, AstraZeneca, Celltrion. Consulting or advisory role: Genentech/Roche, Seattle Genetics, Daiichi Sankyo, Macrogenics, Taiho Pharmaceutical, Context Therapeutics, Novartis, Merck, Ionis Pharmaceuticals, Bristol Myers Squibb, AstraZeneca. Research funding<i>:</i> Genentech, Pfizer. Sara Tolaney. Consulting or advisory role<i>:</i> Novartis, Pfizer, Merck, Lilly, Nektar, NanoString Technologies, AstraZeneca, Puma Biotechnology, Genentech, Eisai, Sanofi, Celldex, Bristol Myers Squibb, Paxman, Seattle Genetics, Odonate Therapeutics, AbbVie, Silverback Therapeutics, G1 Therapeutics, OncoPep, Kyowa Hakko Kirin, Samsung Bioepis, CytomX Therapeutics, Daiichi Sankyo, Athenex, Immunomedics/Gilead, Mersana, Certara. Research funding: Genentech/Roche, Merck, Exelixis, Pfizer, Lilly, Novartis, Bristol Myers Squibb, Eisai, AstraZeneca, NanoString Technologies, Cyclacel, Nektar, Immunomedics, Odonate Therapeutics, Sanofi, Seattle Genetics. Travel, accommodations, expenses: AstraZeneca, Lilly, Merck, Nektar, Novartis, Pfizer, Genentech/Roche, Immunomedics, Eisai, NanoString Technologies, Puma Biotechnology, Celldex. No other potential conflicts of interest were reported.